Israeli biotech Pharma Two B has announced positive results in its Phase IIb pivotal clinical study of P2B001 for the treatment of early stage Parkinson’s disease. The tests combined two low dose chemicals that separately had limited effect and were dangerous in high dosages.

http://www.pharma2b.com/en/73/Press_Release_5.aspx